TL;DR
**Dermorphin vs PE-22-28** compares two research peptides with distinct biological targets. Dermorphin is a amphibian-derived µ-opioid receptor (MOR) agonist used to probe opioid binding, signaling, and pain-pathway models. PE-22-28 is a short spadin-related peptide studied mainly as a TREK-1 (K2P2.1) potassium-channel modulator in neurophysiology and mood-related circuit work. They share peptide handling and analytical needs but diverge sharply in receptors, readouts, and experimental design. Choose Dermorphin for MOR-centric assays; choose PE-22-28 for TREK-1 / two-pore-domain potassium channel studies. Neither is interchangeable as a drop-in substitute.
What Is Dermorphin in Laboratory Research?
Dermorphin is a heptapeptide originally isolated from the skin of *Phyllomedusa* frogs. Its canonical sequence (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) includes a D-alanine residue that contributes to proteolytic stability and high affinity for the µ-opioid receptor relative to many endogenous opioid peptides.
In research settings, Dermorphin is used to:
- Characterize MOR binding affinity and selectivity versus δ- and κ-opioid receptors
- Probe G-protein coupling, β-arrestin recruitment, and downstream cAMP or MAPK readouts
- Benchmark agonist potency in isolated tissue, primary neuron, or recombinant cell systems
- Explore structure–activity relationships (SAR) around the N-terminal message domain and C-terminal address elements
Because of its potency and MOR bias in many in vitro systems, Dermorphin often appears as a reference agonist alongside morphine, DAMGO, or endomorphin analogs when laboratories map opioid pharmacology.
What Is PE-22-28 in Laboratory Research?
PE-22-28 is a synthetic short peptide related to spadin, a sortilin-derived fragment. It is investigated primarily for interaction with TREK-1 (TWIK-related K+ channel 1; KCNK2), a two-pore-domain potassium channel expressed in brain and other tissues.
Typical research applications include:
- Electrophysiological assessment of TREK-1 current inhibition or modulation in transfected cells or native neurons
- Behavioral and circuit-level models in which TREK-1 function is a hypothesis-driven variable (e.g., stress-response or monoaminergic pathway studies in animals)
- Screening of channel blockers/modulators and comparison with full-length spadin or other PE analogs
- Biochemical work on sortilin–TREK-1 regulatory axes
Unlike classical opioid ligands, PE-22-28 is not framed as an MOR tool; its value in the literature centers on K2P channel pharmacology and related neurophysiological endpoints.
Dermorphin vs PE-22-28: Structural and Physicochemical Profile
| Feature | Dermorphin | PE-22-28 |
| --- | --- | --- |
| Peptide class | Heptapeptide opioid | Short spadin-related peptide |
| Notable residue | D-Ala (position 2) | Linear short sequence optimized from spadin |
| Primary research target | µ-opioid receptor | TREK-1 (K2P) channel |
| Typical readouts | Binding, GTPγS, cAMP, analgesia models* | Patch-clamp, channel current, circuit assays |
| Stability notes | D-amino acid slows some proteases | Short chain; standard peptide storage practices |
\*Animal or tissue models only; research-use context.
Both are supplied as research peptides and require cold, dry storage, protection from repeated freeze–thaw, and verification by HPLC/MS identity and purity before critical experiments. Solubility workflows differ by salt form and sequence hydrophobicity; laboratories should validate vehicle compatibility with the intended assay (e.g., buffer for cells vs. electrophysiology solutions).
Mechanisms and Pathways Studied
Dermorphin: Opioid receptor signaling
Dermorphin engages MOR as an agonist. Research questions often address:
- Orthosteric binding and competition with radiolabeled or fluorescent ligands
- Biased signaling (Gαi/o vs. β-arrestin pathways)
- Cross-talk with other GPCRs or ion channels in pain and reward circuitry models
- Comparative potency versus endogenous opioids and synthetic benchmarks
Experimental systems range from membrane preparations and recombinant HEK/CHO lines to primary DRG neurons and controlled in vivo research models under institutional oversight.
PE-22-28: TREK-1 modulation
PE-22-28 is studied for its ability to modulate TREK-1 activity. Research themes include:
- Inhibition or functional blockade of TREK-1 currents under defined voltage and lipid conditions
- Consequences for neuronal excitability, resting membrane potential, and synaptic integration
- Interaction with sortilin-related trafficking or regulatory mechanisms
- Differentiation from other K2P family members (TREK-2, TRAAK) where selectivity matters
Assays lean heavily on electrophysiology, channel expression systems, and pathway-specific behavioral or neurochemical endpoints in preclinical research—not on classical opioid receptor panels.
Similarities Relevant to Study Planning
Despite different targets, **Dermorphin PE-22-28 comparison** work shares several practical similarities:
1. **Peptide workflow** — Both need identity confirmation, purity documentation, and careful reconstitution.
2. **In vitro first** — Binding, signaling, or channel assays usually precede more complex models.
3. **Control design** — Vehicle, scramble/inactive analogs, and reference ligands/channel modulators strengthen interpretability.
4. **Off-target awareness** — High concentrations can produce nonspecific effects; concentration–response curves and orthogonal readouts help.
5. **Documentation** — Batch-level COAs, storage logs, and method SOPs support reproducibility across opioid and K2P projects alike.
These parallels mean a lab already equipped for one peptide class can often adapt cold-chain, analytical, and QC practices to the other without rebuilding infrastructure.
Key Differences That Drive Experimental Choice
When deciding **Dermorphin or PE-22-28**, align the peptide with the biological question:
- **Receptor vs. channel** — Dermorphin → GPCR (MOR). PE-22-28 → K2P channel (TREK-1).
- **Endpoint suite** — Radioligand/BRET/cAMP/β-arrestin for Dermorphin; voltage-clamp, thallium-flux, or excitability metrics for PE-22-28.
- **Reference standards** — DAMGO, morphine, CTAP/CTOP for opioid work; spadin, known TREK modulators, or genetic TREK-1 tools for PE-22-28 work.
- **Tissue expression context** — MOR-rich circuits (e.g., pain-processing pathways) vs. TREK-1-expressing neuronal populations.
- **SAR focus** — Stereochemistry and opioid message/address motifs (Dermorphin) vs. length and residue optimization from the spadin/PE series (PE-22-28).
Substituting one for the other without redesigning the assay board will not answer the same mechanistic hypothesis.
Practical Considerations for Laboratory Use
Analytical QC
Confirm mass, purity, and, where relevant, stereochemistry (especially D-Ala in Dermorphin). Retain chromatograms and spectra with lab notebooks.
Solubilization and vehicles
Start with manufacturer-recommended solvents, then dilute into assay buffer. Check pH, ionic strength, and DMSO tolerance against cell or slice health criteria. Filter-sterilize only when compatible with peptide recovery.
Assay interference
Peptides can adsorb to plastic or bind serum proteins. Use low-binding plastics, defined BSA levels, and fresh dilutions for quantitative work.
Model selection
Match the model to the target: MOR-expressing lines or tissues for Dermorphin; TREK-1-expressing systems for PE-22-28. Include pharmacological and, when feasible, genetic controls.
Dermorphin vs PE-22-28 in Comparative or Parallel Study Designs
Some groups run parallel arms—opioid pathway modulation alongside K2P modulation—to dissect convergent effects on excitability or behavior in research animals. In those designs:
- Keep dosing, route, and timing decisions strictly within approved research protocols (no human dosing guidance).
- Power statistics separately for each mechanism.
- Avoid assuming additive or antagonistic interactions without direct measurement.
- Report peptide source, lot, and purity so opioid and TREK-1 literatures remain comparable.
Natural product mention: researchers sourcing **Dermorphin** for MOR panels and **PE-22-28** for TREK-1 panels should is researched in the context of them as complementary catalog items, not functional equivalents.
Summary: Selecting the Right Tool
| Research goal | Prefer |
| --- | --- |
| µ-opioid binding / signaling / SAR | Dermorphin |
| TREK-1 current modulation / K2P physiology | PE-22-28 |
| Side-by-side excitability + GPCR study | Both, separate arms |
| Single-target screening cascade | Match peptide to target |
**Dermorphin vs PE-22-28** is ultimately a target-class decision. Use Dermorphin when the hypothesis is opioid-receptor-centric; use PE-22-28 when the hypothesis is TREK-1-centric. Shared peptide-handling discipline improves data quality in both cases, but mechanisms, controls, and readouts remain distinct.
FAQ
Explore Further
Browse our [research peptide catalog](/shop) and review third-party [lab reports & COAs](/lab-reports) for every batch.
---
**Research use only.** The information above is provided for educational and laboratory research purposes only. The compounds discussed are not approved for human or veterinary use, diagnosis, treatment, or the prevention of any disease. Nothing here is medical advice.